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Abstract
Background: Recent progress in ICG (indocyanine green) fluorescence imaging has provided a means by which
we can detect sentinel lymph nodes (SLNs) without the risk of exposing patients to radiation. Neck metastasis is
the most significant prognostic factor. It is imperative that early metastasis can be controlled. Intra-arterial
chemotherapy is performed in order to preserve organs and to improve prognosis when treating oral cancer.
Objective: Evaluate translymphatic chemotherapy targeting SLNs in patients with oral cancer using intra-arterial
chemotherapy. Evaluation will be carried out through the measurement of CDDP concentrations in SLNs.
Methods: Five patients with tongue cancer (T3N0M0) were treated by intra-arterial chemotherapy as neoadjuvant
chemotherapy from November 2010 to June 2011. After a week of chemotherapy, patients underwent surgical
treatment including the partial resection of the tongue and neck dissection. Intra-arterial chemotherapy was
administered at 50 mg/m
2 of CDDP either one or two times weekly. 5 mg of ICG was administered to the lingual
artery at the beginning of surgery. SLNs were detected using ICG fluorescence imaging. 0.1 g of SLNs and non-
SLNs were resected in order to measure CDDP concentrations. The rests of each of the SLNs were examined
intraoperatively by routine frozen pathological examination. SLNs were also identified using radioactive injection
the day prior to surgery.
Results: The mean CDDP concentrations in the SLNs and non-SLNs were 1.2 μg/g and 0.35 μg/g, respectively. Our
intra- arterial infusion revealed that all metastatic lymph nodes, including SLNs, were without false negative SLNs.
However, of 7 metastatic lymph nodes, one was not identified by means of conventional method.
Conclusion: Our findings verified the possibility that intra-arterial chemotherapy may be effective not only for
organ preservation therapy, but also efficient in translymphatic chemotherapy targeting SLNs in patients with oral
cancer through the use of ICG fluorescence imaging.
Introduction
The sentinel lymph node (SLN) is defined as the lymph
node that firstly receives lymphatic drainage from the
primary cancer [1]. The SLN is thought to be the first
possible micrometastatic site via lymphatic drainage
from the primary cancer. Thus, the pathological status
of the SLN can predict the status of all regional lymph
nodes. If the SLN is recognized as being negative for
cancer metastasis, unnecessary dissection may be
avoided and a positive prognosis achieved. This SLN
concept is well established in the treatment of patients
with several types of solid carcinomas, such as mela-
noma and breast cancer [2-4]. The SLN concept has
revolutionized the approach to surgical staging of both
the melanoma and breast cancer, and these techniques
can benefit patients by preventing various complications
due to unnecessary prophylactic dissection when the
SLN is negative for cancer metastasis. Recently, the SLN
concept has been extended to many other solid tumors,
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consider a newly developed translymphatic chemother-
apy procedure targeting the SLN using intra-arterial
chemotherapy for oral cancer to improve prognosis and
to preserve significant organs [7-9].
Objective
Evaluate CDDP concentrations in SLNs and non-SLNs.
Determine the usefulness of translymphatic chemother-
apy targeting SLNs in patients with oral cancer using
intra-arterial chemotherapy.
Method and Patients
Five patients with tongue cancer (T3N0M0) were trea-
ted by intra-arterial chemotherapy as neoadjuvant che-
motherapy from November 2010 to June 2011. After a
week of chemotherapy, surgical treatment including par-
tial resection of the tongue and neck dissection was per-
formed. Intra- arterial chemotherapy was administered
at 50 mg/m
2 of CDDP either one or two times weekly.
CT-angiography confirmed that the areas of tongue can-
cer were stained and that lymph nodes were not stained
(Figure 1). Five mg of ICG was administered via a cathe-
ter positioned in the lingual artery at the beginning of
the surgery (Figure 2). SNLs were detected by ICG
fluorescence imaging (Photodynamic Eye, Hamamatsu
Photonics) and non-SNLs were detected in two subman-
dibular lymph nodes located near the tongue cancer.
These were monitored as controls. In order to measure
CDDP concentrations, 0.1 g of each of the SLNs and
the two non-SLNs were resected and the rests of each
of the SLNs were examined intraoperatively by means of
routine frozen pathological examination. The CDDP
concentrations were measured by atomic absorption
analysis. A conventional method of identifying SLNs
using radioactive injection was also performed the day
before surgery. The pre-treatment characteristics of the
patients are shown in table 1.
Patients’ informed consent was obtained prior to treat-
ment, and this study was approved by the Human Ethics
Review Committee of Juntendo University.
T h ed i f f e r e n c eb e t w e e nt h et w og r o u p sC D D Pc o n -
centrations were tested by Student’s t- test and Wil-
coxon test.; p values < 0.05 were considered to indicate
significance.
Results
Detection of SLNs were clearly demonstrated by ICG
fluorescence imaging (Figure 3, 4). The mean number of
SLNs was 5.6 (3-8). ICG fluorescence imaging showed a
greater number of SLNs in our intra-arterial infusion
than seen when injecting radiocolloid intratumor (mean
3.4). SLNs detected by ICG fluorescence imaging
included all of the SLNs detected by the conventional
radioactive method.
Histopathological examination was performed for 29
SLNs and 90 non-SLNs (Table 1). All 5 patients with his-
topathologically verified metastasis in their SLNs demon-
strated positive results in ICG fluorescence imaging. No
false negative cases were identified within each SLN basin.
However, of the 7 metastatic lymph nodes, one was not
identified by means of conventional methods.
The mean CDDP concentrations of SLNs and non-
SNLs were 1.2 μg/g and 0.35 μg/g respectively. The
Figure 1 CT-angiography infusing the lingual artery.C T -
angiography confirmed the stained tongue cancer (a and b)
indicated by triangls. There was no staining in any lymph nodes (c
and d) indicated by arrowheads. Arrows represent the catheter
inserted in the lingual artery.
Figure 2 Tongue cancer after injection of ICG. a: tongue cancer,
b:tongue cancer with ICG fluorescence imaging.
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than non-SLNs. The mean CDDP concentration of ton-
gue cancer was 2.3 μg/g.
No hematological complications were caused by intra-
arterial chemotherapy. All patients are alive with no evi-
dence of disease and are able to consume food as they
were able to before surgery.
Discussion
Chemoradiation therapy has significantly enhanced the
preservation of important organs in the treatment of
head and neck cancer. However, because of severe
mucositis and low sensitivity to chemotherapy, tongue
cancer has not been treated by chemoradiation as often
as other sites of head and neck cancer [10]. CDDP is a
most promising drug for the treatment of head and
neck cancers. To increase the CDDP concentration in
tongue cancer resistant to chemotherapy we have
adopted intra-arterial chemotherapy for the treatment of
advanced tongue cancer. This procedure has resulted in
a positive prognosis and good organ preservation [7,9].
We found that the administration of CDDP to the pri-
mary tongue cancer has a powerful effect on the pri-
mary cancer as well as occult neck metastasis.
As a result, we have hypothesized that intra-arterial
chemotherapy for the treatment of primary tongue
cancer, also results in translymphatic chemotherapy to
control the subclinical metastatic tumor in SLNs. The
schema of translymphatic chemotherapy is illustrated
in Figure 5. This schema shows that CDDP adminis-
tered to the primary tongue cancer moves selectively
to SLNs via lymphatic canals. CDDP is accumulated in
t h eS N L sa n dr e s u l t si nah i g hC D D Pc o n c e n t r a t i o ni n
the SLNs. Compared with the 2.3 μg/g CDDP
Table 1 Patients characteristics
cases site age M/F TNM No of SLNs by radiocolloid No of SLNs by ICG No of non-SLNs
1 tongue 34 M T3N0M0 3 4 11
2 tongue 57 F T3N0M0 3(FN) 6 21
3 tongue 37 M T3N0M0 3 6 14
4 tongue 63 M T3N0M0 4 6 16
5 tongue 59 M T3N0M0 4 7 28
Mean 50 3.4 5.6 18
FN: False Negative, LN: Lymph node
Figure 3 Intraoperative navigation surgery using ICG fluorescence imaging. Number(1~5) means SLNs. a and b represent level II and III
dissection. c and d represent level III and IV dissection.
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mean CDDP concentration measured in SLNs was
recorded at 1.2 μg/g. However, the difference between
the CDDP concentrations of SLNs and tongue cancer
was significant.
In our preliminary study, all SLNs were detected by
ICG fluorescence imaging infused via the lingual artery
in 5 cT3N0 tongue cancer patients. The number of
SLNs resulting from intra-arterial infusion was greater
than could be seen when by means of conventional
Figure 4 Resected specimens. a:Rt side represents the caudal side. Number(1~7) represents SLNs. b:level I, c: level II and III, d: level III and IV.
Figure 5 The schema of translymphatic chemotherapy using intra-arterial chemotherapy. CDDP administered to the primary tongue
cancer moves selectively to SLNs via lymphatic canals and CDDP accumulated in SLNs. The arrows indicate cancer.
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administered to the lingual artery and ICG spread
throughout half of the tongue (Figure 2). ICG moved via
lymphatic canals from half of the tongue including the
tongue cancer. Even in micrometastatic SLNs, an affer-
ent lymphatic sometimes occluded by micrometastatic
cancer based on sentinel navigation or CT lymphograpy
[11]. In our examination, we also did not detect a meta-
static SLN by conventional methods due to occlusion of
afferent lymphatics from the tongue cancer (Figure 6). It
contained CDDP as high as 1.68 μg/g. This was because,
each lymph node has several afferent lymphatics and
ICG or CDDP could move to micrometastatic SLN via
several other afferent lymphatics in the case of intra-
arterial infusion. CDDP was released continuously from
the primary tongue cancer via the translymphatic canal
for a period of over more than one week. CDDP was
selectively accumulated in SLNs and continued to effect
micrometastasis in SLNs over a long period. After a per-
iod of several weeks, the CDDP concentrations between
the primary cancer and SLNs gradually will become the
same and maintained equilibrium. Our intra- arterial
chemotherapy is suspected to contribute not only to pri-
mary organ preservation, but also to a positive prognosis
by controlling the metastatic SLNs. Preservation of
patients quality of life in advanced cT3N0 tongue cancer
is achieved by means of intra- arterial chemotherapy
and through targeting SLN metastasis with translympha-
tic chemotherapy. We believe that ICG fluorescence
imaging is very useful for navigation surgery as there
appear to be no limitations.
An additional reason for difficulties in detecting SLNs
was the close proximity of the primary tumor to the
lymph node basin. This caused difficulties for both
preoperative lymphoscintigraphy and intraoperative radi-
olocalization, because of the well described phenomena
of “shine-through’’ radioactivity and scatter from the
primary site [4]. Specifically, it was particularly difficult
to detect SLNs on the floor of the mouth in any other
sites of head and neck cancers [12,13]. In order to avoid
the influence of ‘shine-through’ we firstly resected the
close primary tumor before sentinel mapping. However,
it was difficult to completely avoid the influence of
‘shine-through’ after resection of the primary tumor. As
for ICG fluorescence imaging, SLNs were clearly
detected even in close proximity to the primary tumor
and ‘shine-through’ could be avoided. The ICG fluores-
cence imaging procedure demonstrated better success
rates of detecting SLNs for patients with tumors in the
floor of the mouth than the radioactivity method.
Further studies will be required to verify the effective-
ness and safety of intra-arterial chemotherapy as a
method of lymphatic chemotherapy for the treatment of
occult lymph node metastatsis. Our results suggest that
a drug delivery system based on the SLN concept should
be developed for local chemotherapy targeting SLNs in
patients with cN0 oral cancer, for whom there is poten-
tial for metastasis in SLNs.
Further investigations may lead to the development of
an e wm i n i m a l l yi n v a s i v em u l timodal therapy targeting
both the primary tumor and SLNs in the near future.
Conclusion
Our study verified the possibility that intra-arterial che-
motherapy may be effective not only for organ preserva-
tion therapy, but also serve as an efficient procedure for
translymphatic chemotherapy targeting SLNs in patients
with oral cancer through the use of ICG fluorescence
imaging. The CDDP concentrations recorded in SLNs
were significantly higher than in non-SNLs.
This novel drug delivery system is feasible for trans-
lymphatic chemotherapy targeting SLNs in patients with
cT3N0 oral cancer with the possibility of occult metas-
tasis in SLNs.
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Figure 6 A metastatic SLN not detected by the conventional
method. a: left side low power magnification. b: right side high
power magnification. This lymph node contained CDDP as high as
1.68 μg/g.
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